Research Paper Volume 11, Issue 16 pp 5975—5991
LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression
Figure 7. Silencing of miR-625 expression neutralizes the actions of the LINC00511 knockdown on ccRCC cells. LINC00511-deficient A498 and 786-O cells were treated with either the miR-625 inhibitor or NC inhibitor. Transfected cells were used in the subsequent functional experiments. (A) The expression levels of miR-625 in A498 and 786-O cells after miR-625 inhibitor or NC inhibitor transfection were measured via RT-qPCR. *P < 0.05 vs. the NC inhibitor group. (B, C) miR-625 and CCND1 protein amounts in the above-mentioned cells were determined by RT-qPCR and western blotting, respectively. *P < 0.05 vs. the si-NC group. #P < 0.05 vs. group si-LINC00511+NC inhibitor. (D–I) The proliferation, colony formation, cell cycle status, apoptosis, migration, and invasiveness of A498 and 786-O cells cotransfected with si-LINC00511 and either the miR-625 inhibitor or NC inhibitor were analyzed by the CCK-8 assay, colony formation assay, cell cycle assay, cell apoptosis assay, and Transwell migration and invasion assays, respectively. *P < 0.05 vs. the si-NC group. #P < 0.05 vs. group si-LINC00511+NC inhibitor.